ATE396967T1 - (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten - Google Patents
(5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthaltenInfo
- Publication number
- ATE396967T1 ATE396967T1 AT01977774T AT01977774T ATE396967T1 AT E396967 T1 ATE396967 T1 AT E396967T1 AT 01977774 T AT01977774 T AT 01977774T AT 01977774 T AT01977774 T AT 01977774T AT E396967 T1 ATE396967 T1 AT E396967T1
- Authority
- AT
- Austria
- Prior art keywords
- chlorobenzoyl
- hydroxy
- salts
- compositions
- compounds
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- MDCKFLPPLUNLBC-UHFFFAOYSA-N 6-(4-chloro-2-hydroxyphenyl)-6-oxohexanoic acid Chemical compound OC(=O)CCCCC(=O)C1=CC=C(Cl)C=C1O MDCKFLPPLUNLBC-UHFFFAOYSA-N 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- WBGUBKSIOVJUIA-UHFFFAOYSA-N 2-amino-6-(4-chloro-2-hydroxyphenyl)-6-oxohexanoic acid Chemical compound OC1=C(C(=O)CCCC(C(=O)O)N)C=CC(=C1)Cl WBGUBKSIOVJUIA-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23033200P | 2000-09-06 | 2000-09-06 | |
| US23723400P | 2000-10-02 | 2000-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE396967T1 true ATE396967T1 (de) | 2008-06-15 |
Family
ID=26924132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01977774T ATE396967T1 (de) | 2000-09-06 | 2001-09-05 | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7495030B2 (de) |
| EP (1) | EP1322595B1 (de) |
| AT (1) | ATE396967T1 (de) |
| AU (1) | AU2001296865A1 (de) |
| DE (1) | DE60134245D1 (de) |
| WO (1) | WO2002019969A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9720025A (sl) | 1996-03-29 | 1999-08-31 | Emishphere Technologies, Inc. | Spojine in sestavki za prenos aktivne snovi |
| US6358504B1 (en) * | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6991798B1 (en) | 1998-08-07 | 2006-01-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| JP2004521857A (ja) | 2000-06-29 | 2004-07-22 | エミスフェアー・テクノロジーズ・インク | 活性剤の送達のための化合物及び組成物 |
| KR20030083725A (ko) | 2001-03-01 | 2003-10-30 | 에미스페어 테크놀로지스, 인코포레이티드 | 비스포스포네이트 전달용 조성물 |
| US7318925B2 (en) | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| WO2005016111A2 (en) | 2003-08-08 | 2005-02-24 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
| WO2005107773A2 (en) | 2004-05-06 | 2005-11-17 | Emisphere Technologies, Inc. | Solid dosage form of wetted heparin |
| RU2530889C2 (ru) * | 2004-05-14 | 2014-10-20 | Эмисфире Текнолоджис, Инк. | Соединения и составы для доставки активных веществ |
| NZ551196A (en) | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| AU2005249410A1 (en) | 2004-05-14 | 2005-12-15 | Emisphere Technologies, Inc. | Aryl ketone compounds and compositions for delivering active agents |
| AU2005244985B2 (en) | 2004-05-19 | 2011-09-01 | Emisphere Technologies, Inc. | Acyclovir formulations |
| CN1968704B (zh) | 2004-05-19 | 2010-12-08 | 爱密斯菲尔科技公司 | 局部用色甘酸制剂 |
| CN101014360A (zh) | 2004-08-03 | 2007-08-08 | 埃米斯菲尔技术公司 | 抗糖尿病口服胰岛素－双胍组合物 |
| GB0427603D0 (en) * | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| WO2006072070A2 (en) | 2004-12-29 | 2006-07-06 | Emisphere Technologies, Inc. | Pharmaceutical formulations of gallium salts |
| WO2006076692A1 (en) | 2005-01-12 | 2006-07-20 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| WO2007011958A2 (en) | 2005-07-15 | 2007-01-25 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
| US8771712B2 (en) | 2006-05-09 | 2014-07-08 | Emisphere Technologies, Inc. | Topical administration of acyclovir |
| JP5475443B2 (ja) | 2006-06-28 | 2014-04-16 | エミスフェアー・テクノロジーズ・インク | 硝酸ガリウム製剤 |
| CA2662853C (en) * | 2006-08-31 | 2016-07-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| ES2841379T3 (es) | 2007-03-13 | 2021-07-08 | Jds Therapeutics Llc | Procedimientos y composiciones para la liberación sostenida de cromo |
| WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| FR2941563B1 (fr) | 2009-01-26 | 2011-02-11 | Commissariat Energie Atomique | Barriere etanche pour microcomposant et procede de fabrication d'une telle barriere. |
| EP2461803B1 (de) | 2009-08-03 | 2018-10-17 | Emisphere Technologies, Inc. | Schnell wirkende naproxenzusammensetzung mit reduzierter wirkung auf magen und darm |
| AU2012223282B2 (en) | 2011-03-01 | 2017-02-02 | Nutrition 21, Llc | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
| CN104884065B (zh) | 2012-09-21 | 2019-01-01 | 强烈治疗剂公司 | 治疗癌症的方法 |
| CA3014308A1 (en) | 2016-02-11 | 2017-08-17 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
| AU2021233893A1 (en) | 2020-03-12 | 2022-08-25 | Baxter Healthcare Sa | Daptomycin formulations containing a combination of sorbitol and mannitol |
| CN113929762B (zh) * | 2021-12-16 | 2022-04-26 | 清华大学 | 3-羟基丁酰化和/或3-羟基戊酰化修饰胰岛素及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583020A (en) * | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CN1313439C (zh) * | 1998-08-07 | 2007-05-02 | 艾米斯菲尔技术有限公司 | 用于送递活性剂的化合物和组合物 |
| JP2004521857A (ja) * | 2000-06-29 | 2004-07-22 | エミスフェアー・テクノロジーズ・インク | 活性剤の送達のための化合物及び組成物 |
-
2001
- 2001-09-05 WO PCT/US2001/041985 patent/WO2002019969A2/en not_active Ceased
- 2001-09-05 AU AU2001296865A patent/AU2001296865A1/en not_active Abandoned
- 2001-09-05 AT AT01977774T patent/ATE396967T1/de not_active IP Right Cessation
- 2001-09-05 DE DE60134245T patent/DE60134245D1/de not_active Expired - Lifetime
- 2001-09-05 US US10/363,726 patent/US7495030B2/en not_active Expired - Fee Related
- 2001-09-05 EP EP01977774A patent/EP1322595B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1322595A4 (de) | 2005-03-23 |
| WO2002019969A2 (en) | 2002-03-14 |
| US20040023847A1 (en) | 2004-02-05 |
| EP1322595B1 (de) | 2008-05-28 |
| DE60134245D1 (de) | 2008-07-10 |
| US7495030B2 (en) | 2009-02-24 |
| EP1322595A2 (de) | 2003-07-02 |
| WO2002019969A3 (en) | 2002-07-11 |
| AU2001296865A1 (en) | 2002-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| ATE387430T1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| ATE391708T1 (de) | Verbindungen und gemische zur verabreichung eines aktiven agens | |
| CO5580776A2 (es) | Formulacion farmaceutica estable en solucion de oxaliplatino | |
| ATE232862T1 (de) | Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| EP1226109A4 (de) | Phenylamin-carbonsäure-verbindungen und zubereitungen zur verabreichung von wirkstoffen | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| ATE329897T1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| DE60126947D1 (de) | Behandlung der glykogenspeicherkrankheit typ ii | |
| MXPA05011076A (es) | Derivados de quinazolina para el tratamiento de cancer. | |
| ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| HUT77627A (hu) | 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények | |
| TW200505452A (en) | Chemical compounds | |
| MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| DE60215313D1 (de) | Indolderivate und deren verwendung als gnrh antagonisten | |
| ATE390124T1 (de) | Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin | |
| ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| DE50114335D1 (de) | Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |